Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024
Quanterix (NASDAQ: QTRX) announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. E.T. on the same day to discuss the results. Investors can access the call via toll-free number (800) 715-9871 with Conference ID 2720617, or through a webcast available on the company's website. A replay of the webcast will be accessible for one year on Quanterix's website.
Quanterix (NASDAQ: QTRX) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 martedì 12 novembre 2024, dopo la chiusura del mercato. L'azienda organizzerà una conference call alle 16:30 ora orientale (E.T.) dello stesso giorno per discutere i risultati. Gli investitori possono partecipare alla chiamata tramite il numero verde (800) 715-9871 con ID conferenza 2720617, o attraverso un webcast disponibile sul sito web dell'azienda. Una registrazione del webcast sarà accessibile per un anno sul sito web di Quanterix.
Quanterix (NASDAQ: QTRX) anunció que publicará sus resultados financieros del tercer trimestre de 2024 el martes, 12 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. hora del Este (E.T.) el mismo día para discutir los resultados. Los inversionistas pueden acceder a la llamada a través del número gratuito (800) 715-9871 con el ID de conferencia 2720617, o a través de un webcast disponible en el sitio web de la empresa. Una repetición del webcast estará accesible durante un año en el sitio web de Quanterix.
Quanterix (NASDAQ: QTRX)는 2024년 11월 12일 화요일 시장 종료 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 동부 표준시(E.T.)에 결과를 논의하기 위한 콘퍼런스 콜을 개최할 것입니다. 투자자들은 무료 전화번호 (800) 715-9871로 전화하여 컨퍼런스 ID 2720617로 참여하거나 회사 웹사이트에서 제공되는 웹캐스트를 통해 접속할 수 있습니다. 웹캐스트의 재생은 Quanterix의 웹사이트에서 1년 동안 이용 가능합니다.
Quanterix (NASDAQ: QTRX) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024, après la fermeture du marché. L'entreprise tiendra une conférence téléphonique à 16h30 (E.T.) ce même jour pour discuter des résultats. Les investisseurs peuvent accéder à l'appel via le numéro gratuit (800) 715-9871 avec l'ID de conférence 2720617 ou via un webinaire disponible sur le site web de l'entreprise. Un replay du webinaire sera accessible pendant un an sur le site de Quanterix.
Quanterix (NASDAQ: QTRX) gab bekannt, dass die Finanzergebnisse für das dritte Quartal 2024 am Dienstag, den 12. November 2024, nach Marktende veröffentlicht werden. Das Unternehmen wird am selben Tag um 16:30 Uhr (E.T.) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über die gebührenfreie Nummer (800) 715-9871 mit der Konferenz-ID 2720617 an dem Anruf teilnehmen oder über ein Webcast, das auf der Unternehmenswebsite verfügbar ist. Eine Aufzeichnung des Webcasts wird für ein Jahr auf der Website von Quanterix zugänglich sein.
- None.
- None.
Quanterix will issue a press release regarding third quarter 2024 financial results prior to the conference call on Tuesday, November 12, 2024, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/.
To pre-register for the conference call with a webcast link click here. For audio use the following dial-in number and passcode:
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105557132/en/
Media:
Marissa Klaassen
(978) 488-1854
media@quanterix.com
Investor Relations:
Amy Achorn
(978) 488-1854
ir@quanterix.com
Source: Quanterix Corporation
FAQ
When will Quanterix (QTRX) report Q3 2024 earnings?
How can I listen to Quanterix (QTRX) Q3 2024 earnings call?
Where can I find the replay of Quanterix (QTRX) Q3 2024 earnings call?
